biotech / news / / The Boston Globe
Ajax's lead medicine is a once-daily pill in the early stages of study for myelofibrosis.
Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, including milestones.
KEY POINTS
- Ajax's lead drug is an early-stage, once-daily pill for myelofibrosis, with key data expected this year.
- The Ajax acquisition follows Lilly's $7 billion Kelonia buyout to access blood cancer gene therapies.
- Lilly was an original investor in Ajax and seeks to improve upon JAK2 inhibitor cancer medicines.
COMPANIES
Summarized by Newsio from The Boston Globe. How we summarize →